Pure MHC, LLC is a discovery and development company with platform technology and expertise in disease-specific (HLA Class I and Class II) target identification and validation, as well as immunotherapeutic drug development for cancer, infectious, and autoimmune diseases. Pure MHC provides collaborative support to researchers in epitope validation, development, and therapeutic exploitation through expansive HLA experience, and expertise in mass spectrometry, proteomics, peptidomics, informatics, tissue culture, epitope screening & validation, peptide binding, HLA extraction, as well as the transfection, production, and purification of the company’s proprietary soluble HLA proteins.
Our mission is to support and enable the creation of novel therapeutics for the treatment of cancer, autoimmune, and infectious disease by leveraging the human leukocyte antigen (HLA) system to selectively identify and eliminate diseased cells.
Pure MHC is a recognized world leader in the HLA system, with well over 100 years of cumulative team experience and thought leadership in the field, and deep domain expertise in antigen discovery, processing, and presentation.
Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC’s proprietary offering of MHC peptide targets for oncology with Myrio’s revolutionary Retained Display™ (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.
“Myrio’s platform is not just an outstanding scientific fit, the collaboration represents a unique and exciting way for Pure MHC to deploy its novel target assets strategically.”
President, Pure MHC